AzTrials
AzTrials

AsthmaREACTNCT07914010

Reducing Exposure With Air Cleaners and Technology

A study testing Air Cleaner, PM2.5 Monitor with Visual Air Quality Indicator and Educational Materials in people with Asthma and COPD (Chronic Obstructive Pulmonary Disease), run by University of California, Berkeley at 3 sites in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Fine particulate matter (PM2.5) is a type of air pollution made up of extremely tiny particles that can harm our health. Because PM2.5 particles are so small, they can travel deep into the lungs when we breathe. Read more about this study

Who is it for?
Ages 13 years and older
What is being tested?
Air Cleaner, PM2.5 Monitor with Visual Air Quality Indicator and Educational Materials
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
3 sitesUnited States
Study dates
Nov 2026to Sep 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Reside in Bayview Hunters Point as defined by the California Assembly Bill 617 (AB617) map, and
  • Have at least one residing person (≥13 years old) with a chronic respiratory health condition (asthma or COPD).
  • Our overarching goal is to recruit one individual participant per household. However, if recruitment proves to be difficult, we will permit more than 1 individual (adult or participant) to participate, with no more than 2 individuals per household recruited. All individuals will be required to have a chronic respiratory heath condition.

Who cannot join

  • Residents who report active use of air cleaners in the past 6 months, and
  • Those who plan to move during the 90-day study period will be excluded.
  • There will be no exclusion criteria based on income, housing type, or health- or indoor air quality impactful behaviors like smoking indoors.

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

United States3 sites
  • University of California, Berkeley

    Berkeley, California, 94720

    Chelsea V Preble, PhD, 510-486-5319, cvpreble@berkeley.edu

  • Brightline Defense Project

    San Francisco, California, 94103

    Eddie Ahn, Esq, 415-252-9700, eddie@brightlinedefense.org

  • University of California, San Francisco

    San Francisco, California, 94110

    Neeta Thakur, MD, MPH, 415-378-6594, neeta.thakur@ucsf.edu

Other trials in United States

About this study

Official title: Reducing Exposure With Air Cleaners and Technology (REACT) in At-Risk Communities

Fine particulate matter (PM2.5) is a type of air pollution made up of extremely tiny particles that can harm our health. Because PM2.5 particles are so small, they can travel deep into the lungs when we breathe. Exposure to PM2.5 can worsen asthma, cause breathing problems, increase the risk of heart attacks, and lead to early death, especially for people with existing heart or lung conditions. In California's Bayview Hunters Point (BVHP), a San Francisco community already facing high levels of air pollution and health impacts, sources of PM2.5 include industrial activity, commuter traffic, heavy-duty diesel trucks, freight trains, and port and maritime activities.

The Reducing Exposure with Air Cleaners and Technology (REACT) Study is a partnership between UC Berkeley, UC San Francisco, and Brightline Defense. The goal is to see if air cleaners (also called air purifiers) can help reduce indoor PM2.5 levels and improve respiratory health.

Read more

For this study, we'll be recruiting 100 households in BVHP to participate. In each home, we'll monitor indoor PM2.5 levels and the health status of household members who are 13 years old or older and have asthma or chronic obstructive pulmonary disease (COPD). Each home will be part of the study for 90 to 120 days, depending on scheduling. Households must reside in BVHP for the duration of the study and not have used an air cleaner in their home within the last 6 months.

On Day 1, each household will receive a PurpleAir indoor air quality monitor to measure PM2.5 levels in their home.

  • For the first 30 days, we'll measure the home's normal air quality (baseline).
  • After 30 days, each household will receive an air cleaner (Figure 2) with information about how to best use it.
  • At that point, we'll also turn on a PM2.5 indicator light on half of the PurpleAir monitors. For the other half, we'll keep that indicator light turned off. This helps us study whether seeing the air quality in real time changes how people use the air cleaner.
  • For the next 30 days, we'll continue monitoring indoor PM2.5 levels. We'll also track how often the air cleaner is used with smart plug data loggers.
  • After 60 days, if a household isn't using the air cleaner much or it doesn't seem to be working well, we'll offer more training and support.
  • We'll continue monitoring over the final 30 days of the study.
Read the detailed description

Historically and persistently divested communities like Bayview Hunters Point (BVHP) in California's San Francisco Bay Area experience disproportionate air pollution and health burden. Local sources of PM2.5 include heavy industrial activity, commuter traffic, heavy-duty diesel trucks, freight trains, and port and maritime activities. Health-protective guidance in these highly impacted communities would improve if we better understood indoor infiltration of outdoor air pollution, especially during extreme events like Spare the Air Days and wildfire smoke periods.

It has been well documented that air contaminants and pollution have adverse health effects, including increased hospitalizations for respiratory illnesses such as asthma, pneumonia and cardiovascular effects. During climate related events such as wildfires, both indoor and outdoor PM2.5 increase, posing additional adverse health effects. Previous studies have noted that low-cost sensors, such as PurpleAir sensors, are effective at measuring airborne particles. Additionally, previous studies have noted that the use of air filters can help mitigate health effects from wildfire smoke and other causes of air pollution. However, use of air cleaners can often be inconsistent. The present study will build on previous literature to examine whether use of air quality monitors in conjunction with air cleaners can increase air cleaner usage and effectiveness.

This study will be a collaborative partnership between UC Berkeley, UC San Francisco, and Brightline Defense. PurpleAir monitors will be used to quantify PM2.5 concentrations before and after air cleaners are distributed. Using a multistage randomized controlled trial design, we will also evaluate how additional information and training can impact participant use of the air cleaners. We will recruit 100 households in BVHP and monitor indoor PM2.5 concentrations continuously and collect in-the-moment health and behavior data twice weekly for a total of 90 days in each participating household. Once consented, households will be randomized to receive sensors with visual indoor air quality (IAQ) cues (n = 50, PurpleAir Zen light ON; Intervention Arm 1) or sensors without IAQ indicators (n = 50, PurpleAir Zen light OFF; Intervention Arm 2). Additionally, household will be randomized to receive one, two, or all three of the technical assistance methods (texts, short-form videos, or video calls). Participants will be randomized 1:1 using blocks into the control arm or intervention arm. Our randomization schema will attempt to minimize differences in reported respiratory symptoms across the two groups. The use of block randomization also reduces the potential for unbalances with studies that have small sample sizes. At the end of study, all participants will keep the air cleaner (including a replacement filter) and PurpleAir monitor. As compensation for hosting the monitors and taking the questionnaires at the beginning and end of the monitoring period, each participant will receive a stipend at the start of the study and at the end. Additionally, each participant can earn an additional stipend for taking the interval surveys over the course of the study.

Before study recruitment and procedures begin, we will recruit 10 community members to serve on the Community Advisory Board. The CAB will be formed and will follow a hybrid model that includes both key stakeholders and organizations who work in the community as well as BVHP residents. The CAB will be used for internal quality improvement of the research study (i.e., helping develop surveys and outreach materials) and thus does not fall within the realm of research. The CAB's formation and activities are separate from other study procedures. CAB members will be recruited separately from study participants. CAB members will not participate in the study, and study participants will not participate in the CAB. The CAB will meet up to 10 times over the 2-year study period. The CAB will provide feedback on the literature review, provide input on study questionnaires and in-the-moment SMS surveys for the study, advise on the planned study protocol, including eligibility criteria and outreach plan, and co-develop a dissemination plan to ensure the study is incorporated into broader community goals.

Health and behavior data will be collected at baseline, during in-the-moment surveys, and at study completion. The questionnaires and surveys will allow the research team to evaluate potentially confounding factors that may influence the intervention benefits and self-reported health impacts, as well as capture behavior data to assist the research team in interpretation of collected data.

Questionnaires will be distributed at baseline and completion of the study, and will include questions about demographics, household characteristics, baseline health status, and baseline knowledge of IAQ and air cleaners. For demographics, questions will include income, race/ethnicity, gender, education, whether they rent or own their home, and how long they have lived at their current residence. For household characteristics, questions will include address, unit size (number of rooms, approximate square footage), building type (single or multi-level, single- vs multi-family home, etc.), stove type (gas or electric), and presence of heating, ventilation, and air conditioning (HVAC) system or personal air cleaners. The number and age of all household members to assess crowding will also be asked. For baseline health status, we will ask about smoking status, underlying health conditions, and daily symptom burden. Last, we will ask questions about the participant's familiarity with IAQ and air cleaners, including any previous experience with air quality information and using air cleaners.

In-the-moment surveys will be sent by SMS twice per week throughout the 90-day study period and ask questions on occupancy (number of people currently home), recent indoor activities (within the last hour), and health and IAQ status. Recent indoor activities include whether there have been open windows, air cleaner in use, running of HVAC system, cooking using a stove or other appliance, burning candles or incense, and smoking or vaping of any kind. For health and IAQ status, questions will ask about any current respiratory symptoms and the participant's impression of their current IAQ and air cleaner use.

Health outcome will be measured at baseline, during in-the-moment surveys, and at study completion using the Breathlessness, Cough, and Sputum Scale (BCSS) for participants with COPD and the Asthma Control Test for participants with asthma.

The interrupted time series intervention study will be conducted as follows:

Phase 1 (Days 1-30): After consent and enrollment, participants will complete the intake questionnaire. During Home Visit 1, a PurpleAir monitor will be installed in each household, with the IAQ indicator turned OFF. All participants will receive an educational handout on the PurpleAir monitor. We will collect baseline indoor PM2.5 concentrations from the PurpleAir monitors and health and behavior data from in-the-moment surveys over the first 30 days. Our prior work informs this monitoring duration as sufficient for establishing daily average PM2.5 and typical behaviors.

Phase 2 (Days 31-60): During Home Visit 2, an air cleaner will be installed in each household with a data logger to capture use. For the 50 participants in Intervention Arm 1, the visual IAQ indicator on the PurpleAir monitor will be turned ON. For the 50 participants in Arm 2, the visual IAQ indicator on the PurpleAir monitor will remain OFF. All participants will receive an educational handout on the air cleaner and best practices for use. All participants will also receive a fact sheet about the Air Quality Index (AQI). For those in Arm 1, the second half of this fact sheet will describe the IAQ indicator on their PurpleAir monitor. For those in Arm 2, the second half of the fact sheet will share general information about where local air quality information can be found. We will continue to collect baseline indoor PM2.5 concentrations from the PurpleAir monitors and health and behavior data from in-the-moment surveys over this next set of 30 days.

Phase 3 (Days 61-90): All participants will receive additional information and training to explore if more targeted technical assistance increases air cleaner use. Participants will receive technical assistance on air cleaner usage in three different forms: (1) text messages that reinforce air cleaner use through reminders and tips and targets spatial barriers and in-the-moment behaviors; (2) short-form videos that show the participants how to use their air cleaner and share community member perspectives on benefits, safety concerns, and household dynamics; and (3) video calls with study staff to build skills and confidence and reinforce value of using the air cleaner. Participants will be randomized to receive one, two, or all three of these forms of technical assistance. We will continue to collect baseline indoor PM2.5 concentrations from the PurpleAir monitors and health and behavior data from in-the-moment surveys over this next set of 30 days.

At the end of the 90-day study period, participants will complete the outtake questionnaire. During Home Visit 3, researchers will download PurpleAir and air cleaner logger data. The power logger will be removed. Participants keep the PurpleAir monitor and air cleaner, with a spare replacement filter. For those in Arm 2, the visual IAQ indicator will be turned ON and the corresponding educational material will be shared.

Perceived benefits, including perceived respiratory improvements, will be qualitatively assessed by semi-structured interviews with participants at the end of the study. Interviews will last approximately 30 minutes and ask about use of air cleaners, including factors that may contribute to increase (e.g., IAQ indicators, extra support) and decrease (e.g., motivation, belief about efficacy) and perceived IAQ and health benefits. Interviews will be audio recorded, transcribed, and coded using an inductive approach (i.e., examine for emerging patterns and themes from interviews). Final thematic analysis will be completed in partnership with CAB.

The installation of the PurpleAir monitors and air cleaners will follow a standardized method. Both will be placed in the same room, either the participant's bedroom or in a central, communal area like the living room. PurpleAir sensors will be installed on a non-floor surface with at least one foot of clearance on all sides, away from any vents, PM2.5 sources like candles, and windows that may be opened. PurpleAir monitor readings will be stored locally to an SD card that is retrieved during Home Visits 2 and 3. When installed, the air cleaner will be installed in the same room as the PurpleAir and placed at least three feet away from the monitor. The air cleaner will be installed with an energy data logger to determine usage and speed setting; data will be downloaded during Home Visit 3 when the energy data logger is uninstalled. The air cleaner is Energy Star rated and certified by the California Air Resources Board, meaning these devices use less energy and do not produce significant ozone. Collected data from the PurpleAir and cleaner use loggers will be assigned a unique identification and will not include any identifiable information of the participant. During installation, technicians will survey the home and make a rough sketch of the layout with dimensions using a laser distance finder to estimate the total volume of the household. No personal or identifiable information will be stored with study data.

Each household and its installed PurpleAir monitor, air cleaner, and cleaner use logger will have a unique ID assigned to them. This unique household ID will be assigned to study participants upon enrollment and linked to unique participant ID. The linked datasets for PM2.5 concentrations, air cleaner use, responses from the questionnaires and surveys, and reported health outcomes will not include any identifying information like participant name, address, or date of birth. The PurpleAir monitor will not be registered with any identifying information. The PurpleAir Monitors will be registered with an assigned number and with a study email address and a proxy physical address. The data stored on PurpleAir will be linked only to the monitor number and a proxy address but will not be linked to any participant identifying information. Data will only be used for the purpose of this study. Information collected through the monitors is used only for aggregate analysis. No personal or identifiable information will be stored with study data; it will be stored on an encrypted HIPAA-compliant, password-protected cloud server at UCSF.

We will leverage the existing publicly accessible networks of low-cost PM2.5 monitors that have been deployed in BVHP. Indoor monitors will be paired to the nearest outdoor sensor to characterize infiltration, indoor/outdoor ratios, and identify the indoor emissions signal relative to the outdoor background.

We will assess the changes in PM2.5 and self-reported health outcomes over the intervention periods relative to the baseline. Air cleaner usage and speed settings will be verified with the recorded energy consumption data. To characterize the relationships between indoor and outdoor PM2.5, we will determine indoor/outdoor ratios and infiltration factors (Finf). We will utilize morphological algorithms to identify and separate indoor episodic PM2.5 peaks from the indoor baseline, which will be further decomposed into persistent indoor-generated and infiltrating outdoor-generated PM2.5. We will then use modified random component super-composition to estimate Finf. To evaluate the efficacy of air cleaners, we will determine decay rates for each identified indoor episodic event. Household-specific total average PM2.5, indoor episodic PM2.5, and PM2.5 decay rates comprise our PM2.5 exposure metrics of interest. We will employ segmented regression models to assess the changes in these exposure metrics over the study course. Each metric will be modeled as a function of the intervention and covariates, e.g., outdoor PM2.5 concentration, Finf, time of day, season, and self-reported behaviors like opening windows. These segmented models will account for the clearly defined interruptions in the PM2.5 time series data resulting from the phased interventions. Inclusion of random effects will account for autocorrelation at the household level, and sub-analysis by housing type will be explored for effect modification. Self-reported health outcomes will also be modeled using segmented regression but will include sub-analysis for potential effect modification by individual characteristics like age, gender, and pre-existing and co-occurring diseases. We will isolate and quantify the immediate outcome changes following each intervention, as well as any changes in the trends.

Being tested
Air Cleaner, PM2.5 Monitor with Visual Air Quality Indicator, Educational Materials, Air Cleaner Technical Assistance
Keywords
humans, indoor air pollution, interrupted time series analysis, chronic obstructive pulmonary disease, asthma, fine particulate matter, San Francisco, air quality indicators, multistage randomized control trial design, technical assistance, portable air cleaner, air filtration device
Medical subject headings
Asthma, Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Air CleanerDevice

    During Phase 2 of the study, an air cleaner will be installed in each participant's household. All participants will receive this device and intervention.

  • PM2.5 Monitor with Visual Air Quality IndicatorDevice

    To assess how visual input from a low-cost particulate matter monitor can increase the use and effectiveness of air cleaners, participants will be randomized to receive monitors with a visual indoor air quality indicator (Arm 1, intervention) and without a visual indoor air quality indicator (Arm 2, control). Participants will be randomized 1:1 using blocks into the intervention arm or control arm.

  • Educational MaterialsBehavioural

    All participants will receive educational materials about the PurpleAir monitor, air cleaner and its best use, and the Air Quality Index. For those in Arm 1, the second half of the Air Quality Index fact sheet will describe the visual air quality indicator on their PurpleAir monitor. For those in Arm 2, the second half of the fact sheet will share general information about where local air quality information can be found.

  • Air Cleaner Technical AssistanceBehavioural

    To evaluate how additional information and/or engagement can further impact air cleaner use and effectiveness, we will provide additional technical assistance on air cleaner usage in three different forms: (1) text messages that reinforce air cleaner use through reminders and tips and targets spatial barriers and in-the-moment behaviors; (2) short-form videos that show the participants how to use their air cleaner and share community member perspectives on benefits, safety concerns, and household dynamics; and (3) video calls with study staff to build skills and confidence and reinforce value of using the air cleaner. Participants will be randomized to receive one, two, or all three of these forms of air cleaner technical assistance.

Study groups in NCT07914010
Study groupRoleWhat they receive
Visual Air Quality Indicator OnExperimentalParticipants in this arm will have the visual air quality indicator on their PurpleAir particulate matter monitor turned on during Phase 2 of the study. This experimental arm will test how the use of an air quality monitor with a visual indicator in conjunction with an air cleaner may increase the use and effectiveness of the air cleaner.
Receives: Device: Air Cleaner; Device: PM2.5 Monitor with Visual Air Quality Indicator; Behavioral: Educational Materials; Behavioral: Air Cleaner Technical Assistance
Visual Air Quality Indicator OffActive comparatorParticipants in this arm will have a PurpleAir particulate matter monitor with the visual air quality indicator turned off for the duration of the study. This will serve as the control to the experimental arm, representing air cleaner usage on its own and without an indoor air quality indicator.
Receives: Device: Air Cleaner; Behavioral: Educational Materials; Behavioral: Air Cleaner Technical Assistance

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Air Quality: Absolute Change in Daily Average Indoor Fine Particulate Matter (PM2.5) Concentration

    Indoor PM2.5 concentrations, measured continuously using PurpleAir monitors and expressed in micrograms per cubic meter (µg/m³), will be summarized as daily averages. To evaluate the impact of the air cleaner intervention on air quality, absolute changes in daily average PM2.5 concentrations (µg/m³) will be assessed across the baseline (30 days) and air-cleaner intervention (60 days).

    Measured: Baseline (Days 1-30), initial intervention (Days 31-60), and targeted technical assistance (Days 61-90)

  2. Air Quality: Percent Change in Daily Average Indoor Fine Particulate Matter (PM2.5) Concentration

    Indoor PM2.5 concentrations, measured continuously using PurpleAir monitors and expressed in micrograms per cubic meter (µg/m³), will be summarized as daily averages. To evaluate the impact of the air quality indicator intervention on air quality, relative (%) differences in daily-average PM2.5 will be assessed across the baseline, air-cleaner intervention, and targeted technical-assistance periods and compared between households with and without visual air quality indicators (Arm 1 vs Arm 2).

    Measured: Baseline (Days 1-30), initial intervention (Days 31-60), and targeted technical assistance (Days 61-90)

  3. Difference in Self-Reported Respiratory Symptoms using Breathlessness, Cough, and Sputum Scale (BCSS) or Asthma Control Test (ACT)

    Self-reported respiratory symptoms will be scored using the BCSS instrument for participants with chronic obstructive pulmonary disease (COPD) and with the ACT for those with asthma. To evaluate the respiratory symptom changes with the introduction of the air cleaner, differences in scores will be assessed across the baseline, air-cleaner intervention, and targeted technical-assistance periods and compared between households with and without visual air quality indicators (Arm 1 vs Arm 2).

    Measured: Baseline (Days 1-30), initial intervention (Days 31-60), and targeted technical assistance (Days 61-90)

Secondary outcomes (1)
  1. Air Quality: Change in Decay Rate of Episodic Indoor Emission Events

    Indoor PM2.5 concentrations, measured continuously using PurpleAir monitors and expressed in micrograms per cubic meter (µg/m³), will be evaluated to identify episodic indoor emission events (e.g., PM2.5 concentration peaks above the indoor baseline). For each indoor episodic event, a decay rate will be calculated. Using the air cleaner loggers, each episodic event will be categorized by air cleaner usage and speed (0 = off vs speeds 1-4) . To evaluate the efficacy of the air cleaners, differences in decay rates will be assessed across the baseline, air-cleaner intervention, and targeted technical-assistance periods and compared between households with and without visual air quality indicators (Arm 1 vs Arm 2).

    Measured: Baseline (Days 1-30), initial intervention (Days 31-60), and targeted technical assistance (Days 61-90)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2026
  2. Study startNov 2026 (estimated)
  3. Primary completionSep 2027 (estimated)
  4. Study completionSep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Using an interrupted time series design and a multistage randomized control trial design, we will assess how inputs like indicators from low-cost PM2.5 monitors and technical assistance can increase the use and effectiveness of air cleaners.
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07914010
Sponsor's protocol ID
25-43426
Other IDs
24RD012
Acronym
REACT
Status last verified
Oct 2026
First submitted
28 Oct 2026
Last updated
3 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is currently no plan to make IDP available outside of the REACT Study Team. Study findings will be shared through aggregate results.

Publications

  • Szeszulski J, Guastaferro K. Optimization of implementation strategies using the Multiphase Optimization STratgey (MOST) framework: Practical guidance using the factorial design. Transl Behav Med. 2024 Sep 3;14(9):505-513. doi: 10.1093/tbm/ibae035.

    PubMed 38906703
  • Lunderberg DM, Liang Y, Singer BC, Apte JS, Nazaroff WW, Goldstein AH. Assessing residential PM2.5 concentrations and infiltration factors with high spatiotemporal resolution using crowdsourced sensors. Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2308832120. doi: 10.1073/pnas.2308832120. Epub 2023 Dec 4.

    PubMed 38048461
  • Singer BC, Delp WW. Response of consumer and research grade indoor air quality monitors to residential sources of fine particles. Indoor Air. 2018 Jul;28(4):624-639. doi: 10.1111/ina.12463. Epub 2018 May 14.

    PubMed 29683219
  • Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013 Nov-Dec;13(6 Suppl):S38-44. doi: 10.1016/j.acap.2013.08.002.

    PubMed 24268083
  • Leidy NK, Rennard SI, Schmier J, Jones MK, Goldman M. The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation. Chest. 2003 Dec;124(6):2182-91. doi: 10.1378/chest.124.6.2182.

    PubMed 14665499
  • DeVries R, Kriebel D, Sama S. Validation of the breathlessness, cough and sputum scale to predict COPD exacerbation. NPJ Prim Care Respir Med. 2016 Dec 1;26:16083. doi: 10.1038/npjpcrm.2016.83.

    PubMed 27906157
  • Mansouri A, Wei W, Alessandrini JM, Mandin C, Blondeau P. Impact of Climate Change on Indoor Air Quality: A Review. Int J Environ Res Public Health. 2022 Nov 24;19(23):15616. doi: 10.3390/ijerph192315616.

    PubMed 36497689

Questions about this trial

What is this clinical trial studying?

A study testing Air Cleaner, PM2.5 Monitor with Visual Air Quality Indicator and Educational Materials in people with Asthma and COPD (Chronic Obstructive Pulmonary Disease), run by University of California, Berkeley at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Air Quality: Absolute Change in Daily Average Indoor Fine Particulate Matter (PM2.5) Concentration (time frame: Baseline (Days 1-30), initial intervention (Days 31-60), and targeted technical assistance (Days 61-90)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07914010, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in